Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Exclusion Criteria

• •Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product
• •Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator
• •Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current DSM-IV-TR Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)
• •Subjects experiencing acute depressive symptoms within the past 30 days
• •Subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history
• •Subjects with a significant risk of violent behavior; who represent a risk of committing suicide
• •Subjects with clinically significant tardive dyskinesia
• •Subjects currently treated with insulin for diabetes.